Vaxcyte Inc. Common Stock vs Invesco NASDAQ 100 ETF — how do they compare? Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B), while Invesco NASDAQ 100 ETF trades at $297.05 (market cap $111.77B). The key difference: Invesco NASDAQ 100 ETF is far larger — about 10.6× Vaxcyte Inc. Common Stock's market cap, and Vaxcyte Inc. Common Stock is more actively traded (2,644,694 versus 2,346,098). Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and Invesco NASDAQ 100 ETF for 56 Days on average.
| PCVX | QQQM | |
|---|---|---|
Market Cap | $10.51B | $111.77B |
Volume | 2,644,694 | 2,346,098 |
Sector | Health | Broad Market / Factor |
52-Week High | $73.82 | $312.76 |
52-Week Low | $40.32 | $229.87 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $9.14B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
QQQM trades at $306.18, down 0.33% with a bullish technical signal from moving averages. The ETF's lower 0.15% expense ratio compared to QQQ's 0.18% provides a cost advantage, though trading spreads may offset this benefit. Recent institutional buying includes QRG Capital Management increasing its position by 207.5% in Q2 2026. Technical indicators show neutral oscillators with key support at $304-$306 and resistance at $308-$310.
QQQM offers exposure to Nasdaq-100 growth stocks with competitive fees, but faces competition from alternatives like SCHG and QQQE. The ETF's performance depends on technology sector leadership, with concentration risk in top holdings. Recent news highlights tax implications of similar ETFs, emphasizing the importance of understanding distribution characteristics for long-term returns.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →